KR20240025504A - Ulk1/2 억제제 및 이의 용도 - Google Patents

Ulk1/2 억제제 및 이의 용도 Download PDF

Info

Publication number
KR20240025504A
KR20240025504A KR1020237038446A KR20237038446A KR20240025504A KR 20240025504 A KR20240025504 A KR 20240025504A KR 1020237038446 A KR1020237038446 A KR 1020237038446A KR 20237038446 A KR20237038446 A KR 20237038446A KR 20240025504 A KR20240025504 A KR 20240025504A
Authority
KR
South Korea
Prior art keywords
alkyl
pharmaceutically acceptable
solvate
stereoisomer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237038446A
Other languages
English (en)
Korean (ko)
Inventor
마틴 앰블러
에드워드 자일스 엠시버
치도창우 음팜한가
시몬 오스본
Original Assignee
라이프아크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라이프아크 filed Critical 라이프아크
Publication of KR20240025504A publication Critical patent/KR20240025504A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020237038446A 2021-04-07 2022-04-06 Ulk1/2 억제제 및 이의 용도 Pending KR20240025504A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171763P 2021-04-07 2021-04-07
US63/171,763 2021-04-07
PCT/IB2022/000182 WO2022214869A2 (en) 2021-04-07 2022-04-06 Ulk1/2 inhibitors and their use thereof

Publications (1)

Publication Number Publication Date
KR20240025504A true KR20240025504A (ko) 2024-02-27

Family

ID=81748947

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237038446A Pending KR20240025504A (ko) 2021-04-07 2022-04-06 Ulk1/2 억제제 및 이의 용도

Country Status (8)

Country Link
US (1) US20240208934A1 (https=)
EP (1) EP4320121A2 (https=)
JP (1) JP2024516359A (https=)
KR (1) KR20240025504A (https=)
CN (1) CN117545751A (https=)
AU (1) AU2022255073A1 (https=)
CA (1) CA3214567A1 (https=)
WO (1) WO2022214869A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024140401A1 (zh) * 2022-12-30 2024-07-04 捷思英达控股有限公司 作为激酶抑制剂的杂环化合物以及包括其的组合物
WO2025045203A1 (zh) * 2023-09-01 2025-03-06 葆元生物医药科技(杭州)有限公司 杂环化合物及其中间体和应用
WO2025045182A1 (zh) * 2023-09-01 2025-03-06 深圳众格生物科技有限公司 Ulk1抑制剂及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
ATE407678T1 (de) * 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
PE20220597A1 (es) * 2019-05-10 2022-04-22 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos

Also Published As

Publication number Publication date
CN117545751A (zh) 2024-02-09
WO2022214869A2 (en) 2022-10-13
CA3214567A1 (en) 2022-10-13
US20240208934A1 (en) 2024-06-27
EP4320121A2 (en) 2024-02-14
WO2022214869A3 (en) 2022-11-24
JP2024516359A (ja) 2024-04-15
AU2022255073A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
US12384782B2 (en) Inhibitors of kinase networks and uses thereof
TWI675028B (zh) 做為週期素依賴型激酶(cdk)抑制劑之2-h-吲唑衍生物及其醫療用途
EP2498607B1 (en) Kinase inhibitors
JP7337395B2 (ja) Cdk4およびcdk6阻害剤としての2h-インダゾール誘導体およびその治療上の使用
CN104903321B (zh) 作为激酶抑制剂的经取代三环苯并咪唑
AU2014309788B2 (en) Novel quinoline-substituted compound
CN119546588A (zh) 吡啶检查点激酶1(chk1)抑制剂及其用途
JP7680619B2 (ja) Parp1阻害薬及びその使用
TW202039489A (zh) Mat2a之雜雙環抑制劑及用於治療癌症之使用方法
KR20240025504A (ko) Ulk1/2 억제제 및 이의 용도
US20260098024A1 (en) Parp1 inhibitors and uses thereof
WO2024118887A1 (en) N-phenyl-pyrazolo[1,5-a]pyridine-3-carboxamide derivatives as wild type c-kit kinase inhibitors for the treatment of urticaria
CA2942751A1 (en) Macrocylic pyridine derivatives
CA3196676A1 (en) Pyrimidine compounds, compositions, and medicinal applications thereof
WO2023241627A1 (en) Cdk8/19 dual inhibitors and methods of use thereof
KR20220052333A (ko) 근위축성 측색 경화증 및 관련 장애의 치료를 위한 tdp-43에 결합하는 분자
EP3307726B1 (en) 2-oxo-1,2-dihydropyridine-3-carboxamide compounds and their use as inhibitors of pdk1
HK40106135A (zh) 作为ulk1/2抑制剂的2,4-二氨基嘧啶衍生物及其用途
US20250051337A1 (en) Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
US20250282794A1 (en) Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1
EA048523B1 (ru) Пиримидиновые соединения для применения в качестве ингибиторов map4k1
CN121038788A (zh) 用于抑制yap/taz-tead的苯并哌嗪及相关类似物
OA19873A (en) 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231107

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250402

Comment text: Request for Examination of Application